Cytophage Technologies Ltd. · LS:A4ZZ0X
Cytophage Technologies — Investor Presentation (February 2025)
32 slides from Cytophage Technologies's investor presentation, February 2025
Slide 1: Corporate Presentation February 2025
CO R P O R AT E P R E S E N TAT I O N February 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except fo
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Global Health Crisis caused by overuse of antibiotics has accelerated the need for bacteriophage-based solutions, I.E. Safe, non-toxic and biological Pioneers In Bacteriophage R&D And Production, With Track-record Of International Competitive Awards De-risked, Replicable Techno
Slide 4: A Global Health Crisis
A GLOBAL HEALTH CRISIS Leading Cause of Death by 2050 3,500 people die every day from drug-resistant infections; Deadly E. coli outbreak linked to projected to exceed 10 million deaths per year by 2050. McDonald’s Quarter Pounder burger October 23, 2024 Economic Damage Drug resistance could cause an
Slide 5: One Health – Integrated Approach Required
ONE HEALTH – INTEGRATED APPROACH REQUIRED How resistant bacteria move through our supply chain Antibiotic resistant bacteria Environmental contamination with on harvested foods antibiotic resistant bacteria Use of antibiotics on farm Antibiotic resistant Antibiotic resistant animals can promote bact
Slide 6: Bacteriophages – Natural Predators
BACTERIOPHAGES – NATURAL PREDATORS NATURE’S VERSION OF ANTIBIOTICS How do bacteriophages work? • Most abundant form of life on earth • Bacteria’s natural predators • Viruses that only infect and kill bacteria cytophage.com 6
Slide 7: The Cytophage Solution
THE CYTOPHAGE SOLUTION Improving bacteria’s natural predators for commercially applicable solutions. • Safe and toxin free • GMP capabilities • Lytic life cycle only near completion • 1000’s of strains in CYTOPHAGE MANUFACTURING Cytophage library CYTOPHAGE PHAGES Natural phage CYTOPHAGE TOOLS • Larg
Slide 8: Cytophage to Date
CYTOPHAGE TO DATE RESEARCH & DEVELOPMENT Founded 2016 • Leading Scientific Staff Recruited From Canada’s National Microbiology Lab Prestigious Competitive Wins And The Extensive R&D Labour Pool In Winnipeg • Continued Focus On Modifying And Transforming Phages Into Commercial Phage Solutions • Built
Slide 9: Go To Market Strategy
GO TO MARKET STRATEGY 1 A N I M A L H E A LT H 2 H U M A N H E A LT H Faster Trials Long Timeframe FDA trial phases seen as only benchmark of success – without regulatory red tape yet trial can be timeframe of 7 - 10 years Lower Trial Costs Capital Intensive Capital intensive process that is difficu
Slide 10: Animal Health
SS ANIMAL HEALTH
Slide 11: Market Entry - Poultry
MARKET ENTRY - POULTRY Strategic Rationale Current and Alternative Treatments RESTRICTIONS IN KEY MARKETS Program Type Description Performance • 80% of poultry antibiotics already restricted in key Antibiotics + Conventional ionophores for growth Best Feed Conversion Ratio markets Antibiotic enhance
Slide 12: Animal Health Products – Four Pillars
ANIMAL HEALTH PRODUCTS – FOUR PILLARS BROILERS LAYERS Future market AviPhage Initial Target Market EGGS CARCASS/MEAT Salmonella / E.coli OvaPhage PhageFend Initial Target Market Salmonella / Shingella Emerging Market cytophage.com 12
Slide 13: Phage Trial (Broilers): Visible Results
PHAGE TRIAL (BROILERS): VISIBLE RESULTS June 2023: Aviphage Outperforms Untreated Sample Group With Visible Improvements TM Within 11 Days Untreated DAY 11 DAY 11 DAY 3 cytophage.com 13
Slide 14: Phage Trial (Broilers): Data
PHAGE TRIAL (BROILERS): DATA Results of 2023 Chicken Broiler Pilot with AviPhage TM PILOT UNTREATED RESULTS IMPACT DAYS TO MARKET 34 32 2 DAYS BIRDS TO MARKET EARLIER No. BIRDS SOLD (%) 88.6% 91.2% 2.6 % MORE BIRDS SENT TO MARKET TOTAL BODY WEIGHT (KG) 1113 1122 N/A BIRDS REACHED TARGETED BODY W
Slide 15: Phage Testing (Hatching Eggs): Lab Data
PHAGE TESTING (HATCHING EGGS): LAB DATA Results of laboratory in-vitro testing of hatching eggs using OvaPhage Salmonella Recovered (%) Shigella Recovered (%) 100.00 100.00 75.00 75.00 99% 99% reduction reduction 50.00 50.00 25.00 25.00 0.71% 0.65% 0.00 0.00 Salmonella Bacterial Control Ovaphage Tre
Slide 16: Human Health
HUMAN HEALTH
Slide 17: Landmark Use of Bacteriophage in Canada
LANDMARK USE OF BACTERIOPHAGE IN CANADA November 2023 • One of Dr. Azad’s patients suffered from a severe antibiotic-resistant infection following a joint replacement • With no viable treatment options, the patient faced amputation or death February 2024 • Cytophage delivered a personalized bacterio
Slide 18: Human Phage Therapy
HUMAN PHAGE THERAPY I L L U S T R AT I V E T I M E L I N E C Y T O P H A G E S T R AT E G Y FOCUSED ON THE GROWING CHALLENGE OF Work Flow (Months) 1 2 3 4 PROSTHETIC JOINT INFECTIONS • Annual hospital costs for PJI will reach nearly Bacterial Isolate US$2 billion by 2030* Acquisition Bacterial Analy
Slide 19: Mainstreaming Phage Therapy
MAINSTREAMING PHAGE THERAPY • “Global phage therapy market to reach $116m by 2028 amid rising AMR” January 13, 2025 • “How naturally occurring viruses could help treat superbug infections” December 1, 2023 • “This is my last resort’, Ottawa-area woman says of experimental phage therapy to treat infe
Slide 20: Partnerships Drive Clinical Innovation
PARTNERSHIPS DRIVE CLINICAL INNOVATION Streamlined access to Patient Identification patients best suited to phage therapy PARTNERSHIP WITH THE ORTHOPEDIC INNOVATION CENTRE AT THE CONCORDIA Real-world feedback on HIP & KNEE INSTITUTE Operational Insights deploying treatments in clinical settings Resu
Slide 21: Commercial Approach
COMMERCIAL APPROACH
Slide 22: Large Addressable Markets & Powerful Trends
LARGE ADDRESSABLE MARKETS & POWERFUL TRENDS Large addressable markets Powerful global trends • $100bn antibiotic market for humans • 70 countries with antibiotic restrictions • 86 countries with national action plans for AMR • $5BN antibiotic market for poultry • Increasing number of multinational a
Slide 23: Growth Model & Potential Catalysts
GROWTH MODEL & POTENTIAL CATALYSTS 2023 2024 2025 Total Addressable PRODUCT SETS 2025 Catalysts & Milestones Market + $1 billion POULTRY – Broiler Chickens • OvaPhage Trials (Hatching Eggs) • Distributor Network Growth - LOI POULTRY – Eggs • AviPhage Tests / Milestones • First Large-Scale Poultry Tr
Slide 24: Illustrative Financial Model
ILLUSTRATIVE FINANCIAL MODEL REVENUE RAMP: BROILER CHICKENS BASE CASE: $40M - $50M REVENUE $50,000,000 $40,000,000 $30,000,000 • Target 2025: AviPhage revenue, with 1-2 large customers $20,000,000 $10,000,000 • AviPhage (Broiler chickens) is first product: OvaPhage (Hatching $0 eggs) and PhageFend (
Slide 25: State-of-the-Art Facility
STATE-OF-THE-ART FACILITY • 20,585 sq ft company headquarters (June 2024) • State-of-the-art lab space • Modular manufacturing unit • Office space • Construction and outfitting - ~$1.5M • Future needs • Expanded lyophilizer and autoclave capabilities • Packaging and labelling machine(s) cytophage.co
Slide 26: Non-Dilutive Funding Sources
NON-DILUTIVE FUNDING SOURCES Historic Wins/Funding ($1M+) Targeted Grants ($5-10M) • Nutreco Feedtech Challenge • Strategy developed for applying for non- dilutive grants from public and private • Canadian Falling Walls Lab pitch funding organizations competition • Targeting AMR and infectious disea
Slide 27: Corporate Information
CORPORATE INFORMATION
Slide 28: Management Team
MANAGEMENT TEAM DR. STEVEN THERIAULT HEATHER MEDWICK Chief Executive Officer, Chief Operating Officer Chief Science Officer, Director • MPA, focus on health sector • PhD Synthetic Biology with 25 years of • 15 years experience in leading infectious diseases research experience NGO funded by industry
Slide 29: Board of Directors
BOARD OF DIRECTORS HAROLD WOLKIN MICHAEL COCHRANE Chairman Director • 30 years of experience as an investment banker and financial analyst • Investment banking veteran with more than 30 years of M&A and finance • successfully assisted 50+ companies in going public and acquiring investment experience
Slide 30: Capital Structure
CAPITAL STRUCTURE Capitalization (CYTO.V) Shares Outstanding 53,935,221* Options Outstanding 4,198,875 Warrants Outstanding 7,150,034 Fully Diluted S/O 65,284,130 Options Warrants Strike: <$0.28 1,500,000 Strike: $0.50 - $1.40** 7,150,034 Strike: $0.65 - $1.30* 2,698,875 Total 4,198,875 *11.7 millio
Slide 31: Investment Highlights
INVESTMENT HIGHLIGHTS Global Health Crisis caused by overuse of antibiotics has accelerated the need for bacteriophage-based solutions, I.E. Safe, non-toxic and biological Pioneers In Bacteriophage R&D And Production, With Track-record Of International Competitive Awards De-risked, Replicable Techno
Slide 32: Thank You
THANK YOU [email protected] www.cytophage.com
Cytophage Technologies — Investor Presentation (February 2025) on 6ix